

## **AMOEBA CONFIRMS THE EUROPEAN REGULATORY STAGES**

**Lyon, 5<sup>th</sup> April 2018 - AMOEBA (FR0011051598 - AMEBA)**, producer of a biological biocide capable of eliminating the risk of waterborne bacteria, confirms the dates of the final steps before publication of the Biocidal Products Committee (BPC) decision on the application for *Willaertia magna* active substance approval.

The Company confirms the receipt on April 4<sup>th</sup>, 2018 of the Microorganism Working Group assessment report and draft BPC opinion.

The Company has the opportunity to submit by April 13<sup>th</sup> its comments on both documents, which will serve as a basis for discussions during the BPC session on April 26<sup>th</sup>, 2018.

The BPC opinion should be adopted during this session and made public at the end of May 2018. The decision will be then endorsed by the European Commission in the second half of 2018.

As the content of the documents and discussions cannot be disclosed before publication by the European Chemicals Agency (ECHA), the Company will not be able to communicate the decision prior to the publication of the BPC opinion by the ECHA.

*“The European procedure must take place in full in order to allow a sovereign decision of the BPC. This final discussion and decision of the BPC in Helsinki on April 26<sup>th</sup>, in the presence of Amoéba, will be held under a confidentiality basis according to the provisions of ECHA. Amoéba will have to wait for the reception of the official BPC opinion from ECHA to communicate this information.”*, states **Fabrice PLASSON, Managing Director of AMOEBA.**



#### **About AMOEBA:**

Amoéba's ambition is to become the world leader in the treatment of waterborne bacterial risk, wound care and plant protection. Our BIOMEBA solution is an alternative to chemical products widely used today. Amoéba is currently focusing on the market of industrial cooling towers estimated at €1.7Bn <sup>(1)</sup> on a global chemical biocide market for water treatment, evaluated at €21Bn <sup>(2)</sup>. In the future, the Company is looking at developing new applications such as chronic wound care, estimated at € 751 million <sup>(3)</sup> in the USA, and the biocontrol market for plant protection estimated globally at €1.6Bn <sup>(4)</sup>. Sales of the BIOMEBA product for use in industrial cooling towers is subject the Company being granted local regulatory market authorizations.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and in the United States, Amoéba is quoted on the compartment C of Euronext Paris. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME SME equity savings plan setup. More information on [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

*(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013*

*(2): Sources combined by Amoéba from water treaters, Freedomia, Eurostat et MarketsandMarkets*

*(3): BCC Research, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017*

*(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK*

#### **Contacts :**

##### **Amoéba**

Nathalie COMBROUSSE

Marketing Communication Manager

Tel : (+33)4 81 09 18 15

nathalie.combrousse@amoeba-biocide.com

##### **Actifin**

Ghislaine GASPARETTO

Investors communication

Tel. : (+33)1 56 88 11 11

ggasparetto@actifin.fr